Metabolism of the new antihypertensive agent pinacidil in rat, dog and man
- PMID: 7113255
- DOI: 10.3109/00498258209046793
Metabolism of the new antihypertensive agent pinacidil in rat, dog and man
Abstract
1. The antihypertensive agent pinacidil is eliminated from the body mainly by biotransformation in the liver, followed principally by renal excretion of the metabolites. 2. The metabolism and elimination of pinacidil is similar in rat, dog and man, and is independent of the route of administration. 3. After an oral dose, the 24 h urinary excretion of unchanged pinacidil is 13, 4, and 5% in rat, dog and man, respectively. Faecal excretion in the rat and dog is 2 and 4%. 4. In rat, dog and man the main biotransformation product is the pyridine-N-oxide of pinacidil. Following oral administration of pinacidil, 40, 54 and 54%, respectively, is excreted in the urine as the N-oxide during the first 24 h, and less than 1% in the faeces in rat and dog. 5. Three unidentified minor metabolites were found in plasma, urine and faeces in rat and dog. 6. The major metabolite, the pyridine-N-oxide of pinacidil, has an anti-hypertensive potency about a quarter of that of pinacidil. In animals and human volunteers with normal kidney function, however, the plasma concn. of the N-oxide are always lower than those of the parent compound, so that the metabolite contributes little to the antihypertensive effect of pinacidil.
Similar articles
-
Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-N-oxide following i.v. and oral administration in healthy volunteers.Br J Clin Pharmacol. 1985 Jan;19(1):91-4. doi: 10.1111/j.1365-2125.1985.tb02618.x. Br J Clin Pharmacol. 1985. PMID: 3978025 Free PMC article.
-
Pharmacokinetics and distribution of the new antihypertensive agent pinacidil in rat, dog and man.Xenobiotica. 1982 Mar;12(3):177-85. doi: 10.3109/00498258209046792. Xenobiotica. 1982. PMID: 7113254
-
The metabolic disposition of (S)-2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine in rats, dogs, and humans.Drug Metab Dispos. 1980 May-Jun;8(3):163-7. Drug Metab Dispos. 1980. PMID: 6104580
-
Pinacidil. Preclinical investigations.Drugs. 1988;36 Suppl 7:4-9. doi: 10.2165/00003495-198800367-00003. Drugs. 1988. PMID: 3076134 Review.
-
Some aspects of guanidine secondary metabolites.Fortschr Chem Org Naturst. 1995;66:119-295. doi: 10.1007/978-3-7091-9363-1_2. Fortschr Chem Org Naturst. 1995. PMID: 8847007 Review. No abstract available.
Cited by
-
Arterial vasodilating profile and biological effects of pinacidil in healthy volunteers.Br J Clin Pharmacol. 1991 Jan;31(1):33-9. doi: 10.1111/j.1365-2125.1991.tb03854.x. Br J Clin Pharmacol. 1991. PMID: 2015168 Free PMC article. Clinical Trial.
-
Smooth muscle K+ channel openers; their pharmacology and clinical potential.Pflugers Arch. 1989;414 Suppl 1:S99-105. doi: 10.1007/BF00582256. Pflugers Arch. 1989. PMID: 2674897 Review. No abstract available.
-
Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-N-oxide following i.v. and oral administration in healthy volunteers.Br J Clin Pharmacol. 1985 Jan;19(1):91-4. doi: 10.1111/j.1365-2125.1985.tb02618.x. Br J Clin Pharmacol. 1985. PMID: 3978025 Free PMC article.
-
Long-term effects of pinacidil in hypertensive dialysis patients.Eur J Clin Pharmacol. 1985;28(4):375-80. doi: 10.1007/BF00544353. Eur J Clin Pharmacol. 1985. PMID: 4029243
-
Variable metabolism of pinacidil: lack of correlation with the debrisoquine and trimethylamine C- and N-oxidative polymorphisms.Br J Clin Pharmacol. 1989 Apr;27(4):423-8. doi: 10.1111/j.1365-2125.1989.tb05389.x. Br J Clin Pharmacol. 1989. PMID: 2719898 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical